---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-008761"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T11:49:51.570238+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Hepion in-licenses diagnostic tests from New Day Diagnostics for $0.725M upfront

## Summary
- In-licensed celiac, respiratory multiplex (COVID/flu A/B/RSV), H. pylori, and HCC tests; three have CE marks for EU sale.
- Upfront consideration: $525k cash + $200k in unregistered common stock to New Day Diagnostics.
- Milestone payments up to $17.15M on regulatory, sales, and reimbursement milestones; royalties in upper single to low double digits.
- Binding LOI is effective immediately; termination requires mutual consent. Parties to execute definitive license agreement.

## SEC filing metadata
- accession: 0001641172-25-008761
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000164117225008761/0001641172-25-008761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000164117225008761/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-008761
- JSON: https://secwatch.observer/filing/0001641172-25-008761.json
- Plain text: https://secwatch.observer/filing/0001641172-25-008761.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.